BIOTECHNOLOGY. INVESTMENT. GOVERNANCE
Better decisions. Stronger execution. Lasting value.
JLC Life Sciences advises biotechnology companies, investors, and life sciences innovators on development strategy, operational performance, governance, and investment decisions.
Experience at a glance
25+ years in biopharma
9 therapy approvals
Zero major findings across global inspections
1 exit
$100M+ CRO partnership savings
Multiple M&A, Pharma partnerships, and licensing deals
Experience spanning pre-IND through registration, global clinical operations, regulatory and clinical development, quality oversight, and executive leadership—complemented by current board and investment roles.
Leadership experience spanning global biopharma and biotechnology companies.
〰️
PFIZER
〰️
GILEAD
〰️
ASTELLAS
〰️
IOVANCE
〰️
ELEVAR THERAPEUTICS
〰️
RADIUS HEALTH
〰️
MEDEOR THERAPEUTICS
〰️ PFIZER 〰️ GILEAD 〰️ ASTELLAS 〰️ IOVANCE 〰️ ELEVAR THERAPEUTICS 〰️ RADIUS HEALTH 〰️ MEDEOR THERAPEUTICS
Four situations I am asked into.
Execution is falling behind
The plan is not translating into progress. Progress has stalled, and you need someone who can diagnose why and get it moving.
1
The company is preparing for a bigger step. A financing, a partnership, or a pivotal trial is ahead, and the operation needs to withstand scrutiny.
A critical milestone is approaching
2
You need an operating view before committing capital. Diligence on a development plan, a team, or a company, from someone who has run these programs.
3
Capital is at stake
A life sciences solution needs market traction
4
You are building technology for life sciences customers. You need someone who understands how your buyers make development and quality decisions.
Senior-level judgement. Direct engagement.
When you work with JLC, you work directly with Jennifer Lee—not a rotating consulting team. I bring the perspective of an executive who has led complex development programs, managed global operations, and participated in board and investment decisions.
Engagements are tailored to the decisions and challenges that matter most, with practical recommendations and clear next steps.